Terminé

Bupropion Stereoselective Pharmacokinetics and CYP2D6 Inhibition in Healthy Volunteers

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est testé

Bupropion

Médicament
Qui peut participer

Maladie

+ Processus pathologiques

+ Conditions pathologiques, signes et symptômes

De 18 à 55 ans
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Recherche fondamentale

Phase 1 précoce
Interventionnel
Date de début : juin 2018
Voir le détail du protocole

Résumé

Sponsor principalIndiana University
Dernière mise à jour : 28 janvier 2026
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 5 juin 2018

Date à laquelle le premier participant a commencé l'étude.

This study focuses on understanding how the drug bupropion is processed in the body, specifically in healthy volunteers. Bupropion is a medication often used to help people quit smoking or manage depression. The study aims to thoroughly examine how bupropion and its byproducts behave in the body over time. Additionally, it seeks to determine how bupropion interacts with an enzyme called CYP2D6, which plays a crucial role in breaking down many medications. Participants in this study will have their blood tested to measure the levels of bupropion and its byproducts, as well as the activity of the CYP2D6 enzyme. The primary outcome of the study is to measure the exposure to bupropion and its metabolites, as well as the activity of CYP2D6, by looking at the area under the plasma concentration versus time curves. This will help researchers understand the onset, extent, and offset of CYP2D6 inhibition in relation to the pharmacokinetic profiles of bupropion and its metabolites.

Titre officielBupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
Sponsor principalIndiana University
Dernière mise à jour : 28 janvier 2026
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

28 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Recherche fondamentale

Cette étude cherche à mieux comprendre les mécanismes biologiques à l'origine d'une maladie ou d'un problème de santé, sans viser directement un traitement.



Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

De 18 à 55 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

MaladieProcessus pathologiquesConditions pathologiques, signes et symptômes

Critères

Inclusion Criteria: * Male and female (approximately 1:1) volunteers between the age of 18 and 55 years old and within 32% of your ideal body weight. * Judged healthy without any significant medical condition as determined by and decided from a pre-enrollment screening session that include medical history, laboratory tests such as blood and urine tests, and an electrical tracing of the heart beat (electrocardiogram, EKG). * Individuals who agree to refrain from taking any prescriptions medications, over-the-counter medications, and herbal, dietary, and alternative supplements that may interact with the metabolism of those study drugs at least 2 weeks prior to the start of the study and until study completion. * Nonsmoker or individuals willing to refrain from smoking or use of tobacco or marijuana for at least two weeks prior to and until the completion of the study (the entire study lasts for approximately 32 days). * Willing to commit the time requested for this study Exclusion Criteria: Subjects will be excluded from the study if they: * Are underweight (weigh less than 52 kg or 114 lb) or overweight \[body mass index (BMI) greater than 32\]. * Have laboratory results that do not fall in a healthy range (e.g., blood hemoglobin less than 12.0 mg/dl). * Have baseline EKG readings that are abnormal that could place the patient at the higher risk as decided by the study medical doctor (MD) * Have history of intolerance, allergic reactions (e.g. rash) or other forms of hypersensitivities to any of the study medications (dextromethorphan and bupropion). * Have current alcohol (more than 4 alcoholic drinks per day on a regular basis) or drug abuse. * Have history or current gastrointestinal (digestive) disorders such as persistent diarrhea or malabsorption that would interfere with the absorption of orally administered drugs * Have history or current seizures, hypertension and heart disease or any other cardiovascular disorders * Have history or current psychiatric (mental or brain) disorders (e.g., feeling sad or unhappy, loss of interest in normal activities, worried) such as depression, anxiety, or suicidality or suicide attempts. * Have significantly compromised liver and/or kidney functions. * Have participated in a research study involving intensive blood sampling or have donated blood within the past two months * Are unable or unwilling to stop taking other substances that may interfere with the metabolism of the study drugs (bupropion and dextromethorphan) two weeks prior to and during the entire study period, including prescription medications, over-the-counter medications, herbal or dietary supplements, and alternative medicines. * Are employees or students under supervision of any of the study investigators. * Cannot state a good understanding of this study including risks and requirements; are unable to follow the rules of this study. * Cannot commit the time requested for this study.

Plan de l'étude

Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.
Groupes de traitement
Objectifs de l'étude

3 groupes d'intervention sont désignés dans cette étude

Cette étude ne comporte pas de groupe placebo. 

Groupes de traitement

Groupe I

Expérimental
CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).

Groupe II

Expérimental
CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).

Groupe III

Expérimental
The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.

Objectifs de l'étude

Objectifs principaux

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

Suspendu

Indiana Clinical Research Center (ICRC)

Indianapolis, United StatesOuvrir Indiana Clinical Research Center (ICRC) dans Google Maps
Terminé1 Centres d'Étude